Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | KCNQ4 | P56696 | 4/20 | 0.47 |
| ▸ | KCNQ5 | Q9NR82 | 4/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581478 | 1.00 | HDAC1 (0.55) | HDAC1HDAC3NCOR2HDAC2KCNQ4 | |
| SCHEMBL30059279 | 0.89 | CYP17A1 (0.54) | HDAC1HDAC3HDAC2KCNQ4KCNQ5 | |
| SCHEMBL197036 | 0.89 | CYP17A1 (0.54) | HDAC1HDAC3HDAC2KCNQ4KCNQ5 | |
| SCHEMBL29549489 | 0.88 | HDAC1 (0.50) | HDAC1HDAC3HDAC2KCNQ4KCNQ5 | |
| SCHEMBL826795 | 0.88 | HDAC1 (0.50) | HDAC1HDAC3HDAC2KCNQ4KCNQ5 | |
| SCHEMBL857284 | 0.88 | HTT (0.55) | KCNQ4KCNQ5CYP17A1HTT | |
| SCHEMBL5868867 | 0.87 | AAK1 (0.45) | HDAC1HDAC3NCOR2HDAC2KCNQ4 | |
| SCHEMBL5868883 | 0.87 | AAK1 (0.45) | HDAC1HDAC3NCOR2HDAC2KCNQ4 | |
| SCHEMBL5557083 | 0.85 | KCNQ4 (0.47) | HDAC1HDAC3NCOR2HDAC2KCNQ4 | |
| SCHEMBL5868895 | 0.85 | AAK1 (0.48) | HDAC1HDAC2KCNQ4KCNQ5AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118632841-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-110845425-B | Phthalazine derivative and preparation method and application thereof | 合肥工业大学 | 2023-09-08 | — | — | CN | disclosed |
| WO-2023067354-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023003468-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE (HDAC), AND METHODS, COMPOSITIONS AND USES RELATED THERETO. | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-01-26 | — | — | WO | disclosed |
| EP-2751095-B1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-2751095-B1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113461602-A | Aniline compounds with HDAC (HDAC) inhibitory activity, preparation method, composition and application | 北京华氏信华科生物科技有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-10981933-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-04-20 | — | — | US | disclosed |
| CN-105683166-B | Substituted pyrimidine Bmi-1 inhibitors | PTC医疗公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20200148704-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2020-05-14 | — | — | US | disclosed |
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7235547-B2 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | HOFFMANN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| EP-1651234-A1 | COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050049243-A1 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | HOFFMANN-LA ROCHE INC. | 2005-03-03 | — | — | US | disclosed |
| WO-2005014002-A1 | COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148704-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | HDAC1 1/4885HDAC3 3/4885NCOR2 47/4885 |
| US-20050049243-A1 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | GRM2, GRIK2, GRIA2 | HDAC1 541/4885HDAC3 1304/4885NCOR2 525/4885 |
| US-10981933-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | HDAC1 1/4885HDAC3 3/4885NCOR2 47/4885 |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | HDAC1 3175/4885HDAC3 4463/4885NCOR2 4321/4885 |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | HDAC1 1172/4885HDAC3 1055/4885NCOR2 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.